INT138911

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.31
Pain Relevance 1.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Cxcl9)
Anatomy Link Frequency
spleen 1
CMK 1
Cxcl9 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 110 99.80 Very High Very High Very High
cytokine 49 99.22 Very High Very High Very High
chemokine 42 98.74 Very High Very High Very High
Central nervous system 29 92.64 High High
aspirin 1 88.32 High High
interstitial cystitis 82 88.04 High High
cINOD 1 75.00 Quite High
IPN 6 64.80 Quite High
Spinal cord 6 43.68 Quite Low
Arthritis 3 27.20 Quite Low
Disease Link Frequency Relevance Heat
INFLAMMATION 113 99.80 Very High Very High Very High
Cystitis 140 95.04 Very High Very High Very High
Central Nervous System Disease 25 92.64 High High
Pressure And Volume Under Development 7 91.88 High High
Disease 50 88.88 High High
Interstitial Cystitis 82 88.04 High High
Multiple Sclerosis 46 79.36 Quite High
Nociception 13 77.84 Quite High
Cancer 10 73.96 Quite High
Inflammatory Pain 6 64.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Luciferase reporter assay demonstrated that sulindac inhibited IFNgamma-induced promoter activity of the CXCL9 gene.
Negative_regulation (inhibited) of CXCL9
1) Confidence 0.42 Published 2006 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 17010317 Disease Relevance 0.29 Pain Relevance 0.24
Despite the reduction of serum CXCL9 and CXCL10 levels following anti-CXCL10 Ab treatment(s) of mice given CYP, it remained uncertain whether CXCL10 blockade would improve the pathology of cystitis.
Negative_regulation (reduction) of CXCL9 associated with cystitis
2) Confidence 0.42 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.97 Pain Relevance 0.23
The ability of CXCL10 blockade to modulate local chemokines as well as Th1 cytokine mRNA expression and to facilitate the decline of serum levels of CXCL9 and CXCL10 is an indication of reduced local as well as systemic inflammation.
Negative_regulation (decline) of CXCL9 associated with chemokine, inflammation and cytokine
3) Confidence 0.41 Published 2008 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC2583981 Disease Relevance 0.75 Pain Relevance 0.36
monoclonal antibodies in vivo was demonstrated by suppression of CXCL9 mRNA in the spleen as measured by real-time RT-PCR (P < 0.01) (unpublished data).


Negative_regulation (suppression) of CXCL9 in spleen
4) Confidence 0.32 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2442630 Disease Relevance 0.29 Pain Relevance 0.07
For a clinical perspective, we evaluated the effect of a selective inhibitor of caspase-1 (Ac-YVAD-CMK) on inflammatory hypernociception.
Negative_regulation (inhibitor) of YVAD-CMK in CMK associated with inflammation
5) Confidence 0.02 Published 2010 Journal Mol Pain Section Body Doc Link PMC2959021 Disease Relevance 1.02 Pain Relevance 0.45

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox